Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Is This Telehealth Stock a Buy After the Recent Pullback?: https://www.marketbeat.com/logos/articles/med_20240719104001_is-this-telehealth-stock-a-buy-after-the-recent-pu.jpg
Is This Telehealth Stock a Buy After the Recent Pullback?

Hims & Hers Health, Inc. (NYSE: HIMS) is a prominent player in the telehealth sector, which is part of the larger healthcare sector.  The company has garnered significant attention from

Why This Leading Health Stock is a Buy No Matter the Market Move: https://www.marketbeat.com/logos/articles/med_20240718074551_chart-abt-7182024.png
Why This Leading Health Stock is a Buy No Matter the Market Move

Abbott  Laboratories (NYSE: ABT) is a premier buy-and-hold stock because of its foresightful management, quality operation, portfolio, pipeline, cash flow, and capital return. It’s not always a

Why This Healthcare Stock is a Strong Buy Despite Headwinds: https://www.marketbeat.com/logos/articles/med_20240716075118_chart-unh-7162024ver001.png
Why This Healthcare Stock is a Strong Buy Despite Headwinds

UnitedHealth Group (NYSE: UNH) has headwinds, but its healthcare business and operational quality offset them, setting the stock to hit new all-time highs. The primary culprit is the recent

Strategic Buy Lights Up This Biotech Stock: Time to Invest?: https://www.marketbeat.com/logos/articles/med_20240715092117_chartm-ilmn.jpg
Strategic Buy Lights Up This Biotech Stock: Time to Invest?

Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. This comes after its divestiture and spin-off of

CPI Data Sparks Rally in Biotech Stocks: https://www.marketbeat.com/logos/articles/med_20240715071929_cpi-data-sparks-rally-in-biotech-stocks.jpg
CPI Data Sparks Rally in Biotech Stocks

The biotech sector has significantly lagged behind the overall market and its leading sector, technology, year-to-date. However, following the release of the CPI data on Thursday, the biotech

Top 4 Must-Have Healthcare Stocks for Long-Term Growth: https://www.marketbeat.com/logos/articles/med_20240711100558_top-4-must-have-healthcare-stocks-for-long-term-gr.jpg
Top 4 Must-Have Healthcare Stocks for Long-Term Growth

The healthcare industry represents a substantial and dynamic market sector, presenting many opportunities for investors seeking long-term growth and stability. Factors such as the aging

3 Stock Giants Analysts Are Bullish On Despite Struggles: https://www.marketbeat.com/logos/articles/med_20240705084239_3-stock-giants-analysts-are-bullish-on-despite-str.jpg
3 Stock Giants Analysts Are Bullish On Despite Struggles

Despite their recent struggles, these three industry giants hold the promise of significant upside. With favorable consensus price targets and ratings, attractive P/E valuations, solid earnings

AbbVie Stock: A Perfect Dip for Investors to Buy: https://www.marketbeat.com/logos/articles/med_20240703114110_abbvie-stock-a-perfect-dip-for-investors-to-buy.jpg
AbbVie Stock: A Perfect Dip for Investors to Buy

In a holiday-shortened week, shares of AbbVie Inc. (NYSE: ABBV) are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson

Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex: https://www.marketbeat.com/logos/articles/med_20240702093329_biotech-stock-breakout-ibb-eyes-major-resistance-l.jpg
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex

The biotechnology sector, represented by the iShares Biotechnology ETF (NASDAQ: IBB), has experienced a year of consolidation. With the ETF up just 0.8%, it has underperformed the broader market

Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes: https://www.marketbeat.com/logos/articles/med_20240701132023_charty-pfe.jpg
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S (NYSE: NVO) a

Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market: https://www.marketbeat.com/logos/articles/med_20240630174256_charty-lly.jpg
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market

Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is

Sarepta Therapeutics Stock Soars on FDA Approval: https://www.marketbeat.com/logos/articles/med_20240621103734_sarepta-therapeutics-stock-soars-on-fda-approval.jpg
Sarepta Therapeutics Stock Soars on FDA Approval

Sarepta Therapeutics (NASDAQ: SRPT) is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics' stock price has witnessed a surge of over 40% after receiving

Centene Reaffirms Guidance, But Is it Too Late?: https://www.marketbeat.com/logos/articles/med_20240602155058_chart-cnc.jpg
Centene Reaffirms Guidance, But Is it Too Late?

Managed care health insurance company Centene Inc. (NYSE: CNC) recently saw its share rebound after reaffirming its guidance. This move came just after UnitedHealth Group Inc. (NYSE: UNH) made

Hims & Hers Health Soars on Generic GLP-1 Rollout Plans: https://www.marketbeat.com/logos/articles/med_20240602154511_charte-hims.jpg
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans

Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments for erectile dysfunction (ED) through

Is Cigna Group the Nation's Best-Run Health Insurance Company?: https://www.marketbeat.com/logos/articles/med_20240525153829_chart-ci.jpg
Is Cigna Group the Nation's Best-Run Health Insurance Company?

Health insurance companies in the medical sector have not fared well in 2024. Medicare Advantage (MA) plans were a bountiful source of income until the second half of 2023. Humana Inc. (NYSE: HUM)

CVS Health Stock Has a Silver Lining Called Value: https://www.marketbeat.com/logos/articles/med_20240519153028_chartzy-cvs.jpg
CVS Health Stock Has a Silver Lining Called Value

Integrated healthcare retailer and insurer CVS Health Co. (NYSE: CVS) stock presents a value not seen in years. The medical sector giant saw its shares punished on its Q1 2024 top and bottom line

Will the Biotech Sector Shift From Lagger to Leader?: https://www.marketbeat.com/logos/articles/med_20240509132613_will-the-biotech-sector-shift-from-lagger-to-leade.jpg
Will the Biotech Sector Shift From Lagger to Leader?

The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the

AbbVie Tracking for New Highs in 2024: https://www.marketbeat.com/logos/articles/med_20240507101742_chart-abbv-572024.png
AbbVie Tracking for New Highs in 2024

Shares of AbbVie (NYSE: ABBV) fell hard in the wake of its Q1 earnings report, but the dip is over. The market response to slowing Humira sales is overshadowed by strength in the non-Humira

Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report: https://www.marketbeat.com/logos/articles/med_20240505135039_chartszy-pfe.jpg
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report

Biopharma giant Pfizer Inc. (NYSE: PFE) has given back all its COVID gains and more. Shareholders have sat through a painful two-year selloff from the stock's $61.71 high on December 20, 2021, to

Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher: https://www.marketbeat.com/logos/articles/med_20240430080639_analyst-sentiment-revenue-growth-will-lead-abbvie.jpg
Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher

AbbVie Inc. (NYSE: ABBV) stock is recovering after falling over 4% in the week preceding its earnings report on April 26, 2024. As the market closed on Monday, April 29, ABBV stock posted a gain

Abbott Laboratories Outlook is Healthy: Buy the Dip: https://www.marketbeat.com/logos/articles/med_20240417090953_chart-abt-4172024ver001.png
Abbott Laboratories Outlook is Healthy: Buy the Dip

Abbott Laboratories' (NYSE: ABT) share price was corrected at the end of CQ1 2024 on growth, profitability and capital returns concerns. The FQ1 results, however, belie the fear and have the market

Undervalued UnitedHealth Group Won’t Be For Long: https://www.marketbeat.com/logos/articles/med_20240416091545_chart-unh-4162024ver001.png
Undervalued UnitedHealth Group Won’t Be For Long

UnitedHealth Group's (NYSE: UNH) Q1 results were better than expected for two reasons: First, the stock price is now rebounding from long-term lows and deep value territory with ample upside

Biotech Sector Nears Breakout: Will it Outperform in Q2?: https://www.marketbeat.com/logos/articles/med_20240401185946_biotech-sector-nears-breakout-will-it-outperform-i.jpg
Biotech Sector Nears Breakout: Will it Outperform in Q2?

The popular iShares Biotechnology ETF (NASDAQ: IBB) has formed a bullish consolidation in the upper portion of its 52-week range, hinting at a significant sector-wide breakout. 

The bullish

DexCom Stock Gains from GLP-1 Diabetic Users: https://www.marketbeat.com/logos/articles/med_20240331131923_chart-dxcm.jpg
DexCom Stock Gains from GLP-1 Diabetic Users

DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People with diabetes use CGM systems to

7 Stocks That Will Drive the Weight Loss Drugs Market: https://www.marketbeat.com/logos/articles/med_20240327132929_7-stocks-that-will-drive-the-weight-loss-drugs-mar.jpg
7 Stocks That Will Drive the Weight Loss Drugs Market

The global obesity epidemic has reached unprecedented proportions, causing severe health consequences and placing an immense economic burden on healthcare systems.  Pharmaceutical companies are